InnoSer News
How to bring innovation to the drug development space
Innovation is not only part of InnoSer’s name but is central to its activities. We believe, the solution for the continuously high drug attrition rates resides in addressing the problem already at the preclinical stages of drug development. More specifically, we aim...
Nano+ Project Ends With Promising Results
Currently with no known cure, Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. InnoSer has recently finished a project with promising results in understanding altered...
A day in the life of InnoSer Oncology Study Director Kim Frederix
To provide a range of innovative tools for accelerating drug development, InnoSer brings people from both scientific and business backgrounds together. With our interview series ‘A day in the life of’, let’s take a glimpse into what it is like to be part of this small...
InnoSers Ongoing Commitment to the 3R’s
Throughout modern medicine animal testing has played a critical role in the development of drugs, vaccines, and surgical techniques. These studies have enabled us to save countless lives and build upon research to ultimately cure patients. Aiming to accelerate the...
InnoSer is at AACR with its Oncology Offerings
Innoser is putting oncology development at the forefront of our efforts this year. By attending this year's AACR 2021, we hope to improve our innovative oncology offerings and learn from the best. This year the American Association for Cancer Research is hosting its...
Quality Management At InnoSer Services
As InnoSer transitions from the startup to scale up phase in its journey, it is also taking a number of steps to ascertain its quality management ambitions. Having dedicated personnel, expanding our current list of certifications, organizing formal audits and...
Press Release: InnoSer and its sister company C-Path to offer pathology services in close partnership
Press release | Diepenbeek, 01 April 2021InnoSer and its sister company C-Path to offer pathology services in close partnershipEarly 2021, Belgian headquartered preclinical contract research organization (CRO) InnoSer gathered its brands under the umbrella of InnoSer...
BlastomaBrain: New in vitro platform for oncology drug development
One of the greatest challenges in drug development is ensuring that the safety and efficacy results from early stages (i.e. from tests on cultured cells or animal models) translate well to administrating the drugs to humans. The gap between the results from these...
Press Release: InnoSer and Neurix form a partnership to offer neural organoids for oncology drug development applications
Press release | Leiden, 25 January 2021 InnoSer and Neurix form a partnership to offer neural organoids for oncology drug development applications Commercial availability of the in vitro glioblastoma Minibrain organoid platform paves the way for personalized...
Interested In InnoSer’s Services?
Get in touch with us.
